| 1 |
33766264 | New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. | 2021 Mar 30 |
1 |
| 2 |
33781947 | Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update. | 2021 Jul |
1 |
| 3 |
34849601 | CETP-inhibitors: from HDL-C to LDL-C lowering agents? | 2021 Nov 26 |
2 |
| 4 |
27171534 | Cholesteryl ester transfer protein inhibitors: challenges and perspectives. | 2016 Aug |
1 |
| 5 |
27678430 | Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. | 2016 Sep-Oct |
3 |
| 6 |
27900865 | [Treatment of dyslipidemia - is here still place for CETP-inhibitors?] | Fall 2016 |
1 |
| 7 |
24628035 | Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. | 2014 Sep |
5 |